Sustained demand for GLP-1 receptor agonists has exposed global supply constraints, forcing pharmaceutical developers to expand dedicated peptide synthesis infrastructure.
Manufacturing Scaling Bottlenecks
Active pharmaceutical ingredient (API) production requires precise fill-finish capabilities that current contract manufacturing organizations (CMOs) struggle to provide. Total capital investments in dedicated facility expansions are expected to exceed $15 billion through 2026.